Ra Capital Management, L.P. Buys 20,824 Shares of Artiva Biotherapeutics (NASDAQ:ARTV) Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Director Ra Capital Management, L.P. purchased 20,824 shares of Artiva Biotherapeutics stock in a transaction dated Wednesday, July 29th. The shares were purchased at an average cost of $9.99 per share, with a total value of $208,031.76. Following the acquisition, the director owned 17,304,626 shares of the company’s stock, valued at approximately $172,873,213.74. This trade represents a 0.12% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Friday, July 31st, Ra Capital Management, L.P. acquired 24,944 shares of Artiva Biotherapeutics stock. The stock was purchased at an average cost of $9.93 per share, for a total transaction of $247,693.92.
• On Friday, July 24th, Ra Capital Management, L.P. acquired 41,319 shares of Artiva Biotherapeutics stock. The stock was purchased at an average price of $9.99 per share, for a total transaction of $412,776.81.
• On Thursday, July 23rd, Ra Capital Management, L.P. bought 59,880 shares of Artiva Biotherapeutics stock. The shares were purchased at an average cost of $9.96 per share, with a total value of $596,404.80.
• On Wednesday, July 22nd, Ra Capital Management, L.P. bought 84,124 shares of Artiva Biotherapeutics stock. The stock was purchased at an average price of $9.93 per share, with a total value of $835,351.32.
• On Tuesday, July 21st, Ra Capital Management, L.P. bought 120,582 shares of Artiva Biotherapeutics stock. The stock was purchased at an average price of $9.55 per share, with a total value of $1,151,558.10.
• On Friday, July 10th, Ra Capital Management, L.P. purchased 15,102 shares of Artiva Biotherapeutics stock. The stock was purchased at an average price of $8.97 per share, for a total transaction of $135,464.94.
• On Monday, July 13th, Ra Capital Management, L.P. purchased 6,552 shares of Artiva Biotherapeutics stock. The shares were acquired at an average cost of $8.94 per share, for a total transaction of $58,574.88.
• On Friday, June 26th, Ra Capital Management, L.P. acquired 1,876 shares of Artiva Biotherapeutics stock. The shares were acquired at an average price of $8.98 per share, with a total value of $16,846.48.
• On Thursday, June 25th, Ra Capital Management, L.P. acquired 31,000 shares of Artiva Biotherapeutics stock. The shares were acquired at an average price of $8.88 per share, with a total value of $275,280.00.
• On Tuesday, June 16th, Ra Capital Management, L.P. acquired 124,893 shares of Artiva Biotherapeutics stock. The stock was acquired at an average cost of $8.89 per share, with a total value of $1,110,298.77.

Artiva Biotherapeutics Price Performance

ARTV opened at $10.10 on Friday. Artiva Biotherapeutics, Inc. has a 12 month low of $2.22 and a 12 month high of $14.53. The stock has a market cap of $249.67 million, a P/E ratio of -2.85 and a beta of 2.18. The stock’s 50 day moving average price is $9.01 and its 200 day moving average price is $7.51.

Artiva Biotherapeutics (NASDAQ:ARTV) last announced its quarterly earnings results on Friday, May 8th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.07). Equities analysts anticipate that Artiva Biotherapeutics, Inc. will post -2.45 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on ARTV shares. Weiss Ratings restated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research note on Tuesday, July 21st. HC Wainwright increased their target price on shares of Artiva Biotherapeutics from $15.00 to $35.00 and gave the company a “buy” rating in a research report on Friday, May 8th. Cantor Fitzgerald reissued an “overweight” rating on shares of Artiva Biotherapeutics in a research note on Tuesday, May 26th. Needham & Company LLC restated a “buy” rating and set a $41.00 price target on shares of Artiva Biotherapeutics in a research report on Monday, June 8th. Finally, Wedbush upped their price target on shares of Artiva Biotherapeutics from $23.00 to $40.00 and gave the stock an “outperform” rating in a research note on Monday, May 11th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $39.00.

Institutional Trading of Artiva Biotherapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of ARTV. Citadel Advisors LLC boosted its stake in Artiva Biotherapeutics by 419.3% during the third quarter. Citadel Advisors LLC now owns 798,397 shares of the company’s stock valued at $2,291,000 after buying an additional 644,658 shares in the last quarter. BNP Paribas Financial Markets raised its position in Artiva Biotherapeutics by 14,463.5% in the third quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company’s stock worth $340,000 after acquiring an additional 117,733 shares in the last quarter. Renaissance Technologies LLC raised its position in Artiva Biotherapeutics by 46.8% in the fourth quarter. Renaissance Technologies LLC now owns 116,200 shares of the company’s stock worth $498,000 after acquiring an additional 37,053 shares in the last quarter. Marshall Wace LLP acquired a new stake in Artiva Biotherapeutics in the 4th quarter valued at about $341,000. Finally, Jane Street Group LLC bought a new position in shares of Artiva Biotherapeutics during the 2nd quarter valued at about $67,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.